Douglas W. Axelrod, M.D., Ph.D., has been appointed senior vice president for clinical R&D, Ambrx, Inc.
   
Dr. Axelrod joins the company after a 20-year career at Procter & Gamble Pharmaceuticals. Most recently, he served as vice president of R&D for Discovery, Early Development and Product Development where he accelerated the discovery process, improved the discovery to early development transition and led efficiencies in product development. Dr. Axelrod also led the P&G Worldwide Clinical Bone group, leading drugs such as Didronel and Actonel through late clinical development and regulatory approvals.
   
"Doug has tremendous depth and breadth of experience in drug discovery and development and has been successful in delivering innovative medicines to patients," said Steve Kaldor, Ph.D., Ambrx's president and chief executive officer. "He will be integral to the ongoing build out of Ambrx's development capabilities in support of our rapidly maturing pipeline of clinical and preclinical phase protein drug candidates."
   
Dr. Axelrod added, "I am pleased and excited to join Ambrx at this exciting stage of its development. The company has moved rapidly from proof of concept of the ReCODE technologies to the creation and development of a family of important and practical biologics-based products. I look forward to playing a role in bringing these important products to clinical reality and into the marketplace, both with our collaborators and as independent Ambrx efforts."

News from our sister sites